MILAGEN

Milagen

Biotechnology, 1255 Park Ave Ste B, EMERYVILLE, California, 94608, United States, 1-10 Employees

milagen.com

  • facebook
  • LinkedIn

phone no Phone Number: 51********

Who is MILAGEN

Milagen is a privately held, late-stage, pre-commercial diagnostic company focused on commercializing easy-to-use, non-invasive, in vitro diagnostic (IVD) products designed to fulfill unm...

Read More

map
  • 1255 Park Ave Ste B, EMERYVILLE, California, 94608, United States Headquarters: 1255 Park Ave Ste B, EMERYVILLE, California, 94608, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 7929 | NAICS Code: 813920 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from MILAGEN

MILAGEN Org Chart and Mapping

Employees

Similar Companies to MILAGEN

Octant

  • 51-200 51-200
  • 10 Million to 25 Million $ 10 Million to 25 Million

Slingshot Biosciences

  • 51-200 51-200
  • 10 Million to 25 Million $ 10 Million to 25 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding MILAGEN

Answer: MILAGEN's headquarters are located at 1255 Park Ave Ste B, EMERYVILLE, California, 94608, United States

Answer: MILAGEN's phone number is 51********

Answer: MILAGEN's official website is https://milagen.com

Answer: MILAGEN's revenue is Under $1 Million

Answer: MILAGEN's SIC: 7929

Answer: MILAGEN's NAICS: 813920

Answer: MILAGEN has 1-10 employees

Answer: MILAGEN is in Biotechnology

Answer: MILAGEN top competitors include: Octant , Slingshot Biosciences

Answer: MILAGEN contact info: Phone number: 51******** Website: https://milagen.com

Answer: Milagen is a privately held, late-stage, pre-commercial diagnostic company focused on commercializing easy-to-use, non-invasive, in vitro diagnostic (IVD) products designed to fulfill unmet clinical needs in the prevention, detection, diagnosis, and management of major cancers. We are making the transition to commercialize our novel, proprietary antibody-based blood serum assays for detection of Breast and Colon cancer recurrence in a CLIA setting while we are preparing for a major clinical study to support an intended use for the early detection of major cancers.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access